MX9701531A - Terapia de combinacion para tratar la osteoporosis-polifosfonatos o progestinas y agonistas de estrogenos. - Google Patents

Terapia de combinacion para tratar la osteoporosis-polifosfonatos o progestinas y agonistas de estrogenos.

Info

Publication number
MX9701531A
MX9701531A MX9701531A MX9701531A MX9701531A MX 9701531 A MX9701531 A MX 9701531A MX 9701531 A MX9701531 A MX 9701531A MX 9701531 A MX9701531 A MX 9701531A MX 9701531 A MX9701531 A MX 9701531A
Authority
MX
Mexico
Prior art keywords
polyphosphonates
progestins
combination therapy
estrogen agonists
treat osteoporosis
Prior art date
Application number
MX9701531A
Other languages
English (en)
Other versions
MXPA97001531A (es
Inventor
David B Mclean
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9701531A publication Critical patent/MX9701531A/es
Publication of MXPA97001531A publication Critical patent/MXPA97001531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso de un compuesto de formula I en combinacion con un polifosfonato o una progestina, en la preparacion de composiciones para tratar o prevenir la osteoporisis.
MXPA/A/1997/001531A 1996-02-28 1997-02-27 Terapia de combinacion para tratar la osteoporosis-polifosfonatos o progestinas y agonistas de estrogenos MXPA97001531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1336796P 1996-02-28 1996-02-28
US013367 1996-02-28

Publications (2)

Publication Number Publication Date
MX9701531A true MX9701531A (es) 1998-06-28
MXPA97001531A MXPA97001531A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
CA2198534A1 (en) 1997-08-28
CN1165654A (zh) 1997-11-26
AU1497697A (en) 1997-09-04
KR970061255A (ko) 1997-09-12
JPH107562A (ja) 1998-01-13
IL120265A0 (en) 1997-06-10
EP0792645A1 (en) 1997-09-03

Similar Documents

Publication Publication Date Title
GR1003011B (el) Νεα συνθεση
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
ZA945249B (en) Parathyrold hormone and raloxifene for increasing bone mass
HK1021134A1 (en) Isobutylgaba and its derivatives for the treatment of pain
BG101349A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
PL320484A1 (en) Method of treating diabetes using kgf
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
EP0646007A1 (en) NEW DELTA-17 AND DELTA-20 UNSATURATED AND SATURATED 17 - g (b) -SUBSTITUTED-4-AZA-5-g (a) -ANDROSTAN-3-ON COMPOUNDS AS INHIBITORS OF 5-ALPHA REDUCTASE.
EP1003510A4 (en) METHOD FOR TREATING HEADACHE WITH TOPICAL ANESTHETIC COMPOSITIONS
TW325996B (en) Anti-atherosclerotic composition containing 17α-dihydroequilin
IL104940A0 (en) Method and composition for the treatment of osteoporosis
HU9902668D0 (en) Compounds with growth hormone releasing properties
MY115157A (en) Method and composition for treatment of autoimmune hepatitis
GR3019866T3 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
PL344414A1 (en) Combination therapy for the treatment of tumors
MX9701531A (es) Terapia de combinacion para tratar la osteoporosis-polifosfonatos o progestinas y agonistas de estrogenos.
PH22837A (en) Indolophenanthridines
NZ324615A (en) Method for treating autism using olanzapine
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
BG102060A (en) The use of alendronate for osteoporosis prevention
PL320564A1 (en) Therapeutic set for treating osteoporosis
NZ328739A (en) Treatment of estrogen therapy using 8,9-dehydroesterone
CA2180717A1 (en) Use of phosphorus derivatives of alkaloids for treating endocrinopathies
BG101703A (en) Antiparasitic medicamentous form and method for itsapplication